Loading...
XSHE002773
Market cap2.38bUSD
Jan 16, Last price  
18.72CNY
1D
-1.42%
1Q
-7.19%
Jan 2017
-57.15%
IPO
69.24%
Name

Chengdu Kanghong Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:002773 chart
P/E
16.72
P/S
4.41
EPS
1.12
Div Yield, %
0.79%
Shrs. gr., 5y
1.08%
Rev. gr., 5y
6.29%
Revenues
3.96b
+16.77%
638,209,500796,088,0001,016,532,6001,331,374,4251,476,627,5271,674,518,5412,074,352,0622,540,031,5222,786,497,0002,917,445,1313,257,430,0973,295,430,1203,605,346,5523,389,028,1583,957,459,641
Net income
1.04b
+16.52%
82,447,200108,507,000165,026,400202,745,559315,712,938273,481,710393,813,314496,751,944644,199,027694,943,801718,190,2680421,084,380896,670,0321,044,765,761
CFO
1.22b
+31.70%
108,422,900136,794,400168,858,000281,838,851333,314,772291,375,787481,971,711846,345,107766,862,498350,884,404812,145,677273,315,485494,114,176925,153,3841,218,411,126
Dividend
May 28, 20240.38 CNY/sh
Earnings
May 16, 2025

Profile

Chengdu Kanghong Pharmaceuticals Group Co., Ltd engages in the research, development, production, and sale of biological products, Chinese medicines, and chemical drugs in China. It offers ophthalmic systems, central nervous systems, digestive systems, and other system drugs. The company was founded in 1996 and is headquartered in Chengdu, China.
URL
https://www.cnkh.com/
IPO date
Jun 26, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,957,460
16.77%
3,389,028
-6.00%
Cost of revenue
1,870,267
2,231,510
Unusual Expense (Income)
NOPBT
2,087,193
1,157,518
NOPBT Margin
52.74%
34.15%
Operating Taxes
202,793
164,485
Tax Rate
9.72%
14.21%
NOPAT
1,884,400
993,032
Net income
1,044,766
16.52%
896,670
112.94%
Dividends
(137,920)
(91,946)
Dividend yield
0.82%
0.64%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,598
Long-term debt
2,959
6,536
Deferred revenue
17,308
23,273
Other long-term liabilities
36,600
88,510
Net debt
(4,742,377)
(3,677,235)
Cash flow
Cash from operating activities
1,218,411
925,153
CAPEX
(138,874)
Cash from investing activities
6,616
Cash from financing activities
(130,498)
FCF
2,022,057
541,217
Balance
Cash
4,702,143
3,685,369
Long term investments
43,194
Excess cash
4,547,463
3,515,917
Stockholders' equity
5,308,346
4,930,463
Invested Capital
3,319,841
3,466,545
ROIC
55.53%
29.38%
ROCE
26.50%
16.57%
EV
Common stock shares outstanding
916,461
919,464
Price
18.44
17.53%
15.69
-22.90%
Market cap
16,899,544
17.14%
14,426,389
-22.90%
EV
12,165,055
10,754,226
EBITDA
2,312,896
1,315,790
EV/EBITDA
5.26
8.17
Interest
151
Interest/NOPBT
0.01%